Erasca Inc (ERAS) Stock Forecast & Price Target

Erasca is attractive because its RAS/MAPK strategy is now supported by early clinical proof across two major assets, with ERAS-0015 showing 40% to 57% uORR in 2L+ PDAC and about 60% to 75% uORR in NSCLC while maintaining a median 100% dose intensity at 24 mg and 32 mg. The company also has multiple near-term catalysts, including first ERAS-4001 data in 2H26 and potential registration-enabling ERAS-0015 studies beginning in 2027, which could validate both pan-RAS and pan-KRAS approaches. Financially, Erasca ended 2Q with $384.3M in cash, cash equivalents, and marketable securities, and the July 2026 public offering added $632.5M gross proceeds, reducing balance-sheet risk as it funds the outlined clinical milestones.

Erasca is viewed negatively because its investment case depends on a narrow, highly uncertain RAS/MAPK-focused pipeline that remains concentrated in only two clinical-stage programs, ERAS-0015 and ERAS-4001, plus one discovery-stage asset, leaving execution risk elevated across development, regulation, and eventual commercialization. The company faces material downside from R&D and regulatory setbacks, the possibility that competing therapies emerge or sales fall below expectations, and the added vulnerability of intellectual property disputes or management execution failures. In addition, the mention of M&A missteps underscores that even strategic capital allocation could destroy value, making the overall risk profile especially unfavorable for a clinical-stage precision oncology company.